Tvardi Therapeutics (TVRD)
Develops oral STAT3 inhibitors for cancer and fibrotic diseases.
Something off on this page? Send us feedback.
Develops oral small-molecule STAT3 inhibitors, led by TTI-101 in liver cancer and the follow-on prodrug TTI-109. The clinical-stage pipeline has no approved commercial product or product revenue and relies on external clinical, manufacturing, and research partners.
Develops direct, oral small-molecule inhibitors of STAT3, a signaling target pursued across cancer and fibrotic disease. The clinical-stage pipeline is organized around two related drug candidates rather than marketed products.
TTI-101 is the first-generation compound and remains in the REVERT LIVER CANCER Phase 1b/2 study for hepatocellular carcinoma. TTI-109 is a phosphate prodrug of TTI-101 designed to improve delivery and tolerability after a healthy-volunteer Phase 1 study.
Operates from Sugar Land, Texas, with a compact, research-heavy workforce and relies on third parties for manufacturing, clinical research, and other development work. No product is approved for sale, no product revenue has been generated, and continued operations depend on clinical progress and additional financing.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Jul 8, 2026 | Piper Sandler | Upgrade | Neutral | Overweight | $4 | $13 |
| Jul 8, 2026 | UBS | Upgrade | Outperform | $10 | ||
| Jul 8, 2026 | Raymond James | Upgrade | Market Perform | Outperform | ||
| Jun 8, 2026 | H.C. Wainwright | Target | $9 | |||
| Apr 20, 2026 | Barclays | Downgrade | Equal Weight | Underweight | $5 | $3 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $15.8M · Total debt $145.0K · Total assets $17.5M · Shareholders' equity $8.4M
- Revenue
- $0
- Operating income
- −$6.6M
- Net income
- −$6.5M
No dividends on record.
| Institutions66 holders · as of Mar 31, 2026 | 28.81% | 2.70M shares | |
| Insiders2 holders · as of May 2, 2025 | 7.36% | 690.1K shares | |
| Otherremainder | 63.83% | 5.99M shares |
9.38M company shares as of Aug 21, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
The share count has not been confirmed by a second filing; stakes use it as it stands.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Slate Path Capital LPInstitution | 7.51% | 704,118 | 13Fas of Mar 31, 2026 |
Shaheen WirkInsiderdirector | 4.73% | 443,385 | Form 4filed May 2, 2025 ↗ |
BlackRock, Inc.Institution | 4.14% | 388,075 | 13Fas of Mar 31, 2026 |
Vanguard Capital Management LLCInstitution | 3.67% | 344,708 | 13Fas of Mar 31, 2026 |
Wallace L. Jr HallInsiderdirector | 2.63% | 246,756 | Form 4filed May 2, 2025 ↗ |
| See all 25 → | |||
13F — a manager's quarterly holdings · Form 4 — an insider's transaction report
Insider tradesForm 4
No open-market trades in the last 12 months.
- Bristol-Myers Squibb
Dual overlap in first-line HCC and late-stage IPF development
- AstraZeneca (ADR)
Approved HCC dual immunotherapy with an expanding liver-cancer program
- Merck
Established HCC immunotherapy and a REVERT combination counterpart
- United Therapeutics
Registration-stage inhaled therapy for idiopathic pulmonary fibrosis
- Contineum Therapeutics
Oral Phase 2 IPF program with a distinct antifibrotic mechanism
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Tvardi Therapeutics | $1.89 | +0.96% | $17.6M | — | — | — | — |
| Bristol-Myers Squibb | $67.50 | −0.23% | $138.21B | 14.9 | 10.6 | 2.8 | +5.7% |
| AstraZeneca (ADR) | $164.21 | +1.58% | $250.67B | 24.3 | 15.2 | 4.1 | +6.4% |
| Merck | $152.00 | +0.24% | $374.52B | 121.3 | 17.6 | 5.6 | +5.1% |
| United Therapeutics | $480.00 | −2.43% | $20.88B | 17.6 | 18.9 | 6.6 | −1.9% |
| Contineum Therapeutics | $17.24 | +4.14% | $648.6M | — | — | — | — |
| Median | 20.9 | 16.4 | 4.9 | +5.4% |